Products for Research Use Only
RegisterLogin

HPGDS-IN-1

CAT: 0804-HY-12791-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12791-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
HPGDS-IN-1 (Compound 2[3]) is an hPGDS inhibitor with an IC50 of 12 nM (as measured by fluorescence polarization assay or EIA) . hPGDS-IN-1 can be used in the research of allergic rhinitis and spinal cord neurons[1][2][3].
CAS Number
1234708-04-3
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
PGE synthase
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/hPGDS-IN-1.html
Concentration
10mM
Purity
99.92
Solubility
DMSO : 16.67 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
OC(C)(C)C1=NC(C2=CC(CNC(C(C=N3)=CN=C3C4=CC=CC=N4)=O)=CC=C2)=NO1
Molecular Formula
C22H20N6O3
Molecular Weight
416.43
Precautions
H302, H315, H319, H335
References & Citations
[1]Vandeusen, Christopher L, et al. Phenyloxadiazole derivatives as PGD inhibitors and their preparation, pharmaceutical compositions and use in the treatment of allergic and inflammatory disorders. From PCT Int. Appl. (2011), WO 2011044307 A1 20110414.|[2]Hahn Chang S. Method for treating macular degeneration using syk multikinase inhibitor, an hPGDS inhibitor and a DP antagonist. From PCT Int. Appl. (2010), WO 2010080563 A2 20100715.|[3]Weiberth Franz J, et al. Demonstration on Pilot-Plant Scale of the Utility of 1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD) as a Catalyst in the Efficient Amidation of an Unactivated Methyl Ester. From Organic Process Research & Development (2012), 16 (12), 1967-1969.|[4]González-Llera L, et al. An in vivo drug screen in zebrafish reveals that cyclooxygenase 2-derived prostaglandin D2 promotes spinal cord neurogenesis. Cell Prolif. 2024 May;57 (5) :e13594.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-P71036-01HPGDS, Human
HY-126134-01HPGDS inhibitor 2
HY-146662HPGDS inhibitor 3
HY-RS06341HPGDS Human Pre-designed siRNA Set A
HY-RS23682Hpgds Rat Pre-designed siRNA Set A
HY-RS17229Hpgds Mouse Pre-designed siRNA Set A
HY-N6838-011,1,1,1-Kestohexaose
HY-157129AMPK-α1β1γ1 activator 1
HY-1336231,1,1-Tribromoacetone
HY-149536TWIK-1/TREK-1-IN-1

Alternative Products

CatalogName
C04776HPGDS-IN-1
B1046-1HPGDS inhibitor 1
MBS577074HPGDS-inhibitor-1
MBS200632-01HPGDS
A14444-50HPGDS-IN-1 (SAR191801) 50mg
A12258-200HPGDS inhibitor 1 200mg
A12258-100HPGDS inhibitor 1 100mg

Popular Products